Scholarlink

Background <p>Non-small cell lung cancer (NSCLC), the most common subtype of lung cancer, presents major clinical challenges owing to its highly complex tumor microenvironment and substantial cellular heterogeneity. A comprehensive understanding of the immune landscape—particularly the phenotypic diversity and functional roles of macrophage subpopulations—is critical for identifying novel therapeutic targets and developing more effective treatment strategies.</p> Methods <p>We constructed a comprehensive single-cell atlas of Stage I NSCLC using single-cell RNA sequencing (scRNA-seq) to characterize immune heterogeneity, with particular emphasis on macrophage subsets. Network pharmacology was employed to investigate the interactions between AHSA1 and bioactive compounds derived from the traditional Chinese medicine formulation Yu Ping Feng San (YPFS). To further evaluate these interactions, molecular docking simulations were performed to assess binding affinities and elucidate the potential regulatory effects on macrophage polarization.</p> Results <p>ScRNA-seq analysis revealed heterogeneous macrophage subtypes, each exhibiting distinct roles in tumor progression. AHSA1 was identified as a key regulator of macrophage polarization, with higher expression levels associated with unfavorable prognosis. Through network pharmacology and molecular docking, strong binding affinities were observed between AHSA1 and Yu Ping Feng San (YPFS)-derived compounds, including wogonin, kaempferol, and quercetin. Notably, quercetin displayed the highest binding affinity and exerted the strongest inhibitory effect on M2 macrophage polarization.</p> Conclusion <p>These findings identify AHSA1 as a pivotal regulator of macrophage polarization in NSCLC and position quercetin as a promising macrophage-targeted therapeutic candidate. Furthermore, the results highlight the potential of Yu Ping Feng San (YPFS) as a complementary therapeutic strategy for NSCLC, offering a bridge between traditional Chinese medicine and modern oncology.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Single-cell sequencing and network pharmacology coupled with molecular docking and experimental validation reveal the effects of YPFS on macrophages in stage I non-small cell lung cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月27日

查看全文
  • Hongmin Li,
  • Qitai Zhao,
  • Li Yang,
  • Le Wang,
  • Fanglei Ye,
  • Lei Yang,
  • Peijun Zhang,
  • Yi Zhang

摘要

Background

Non-small cell lung cancer (NSCLC), the most common subtype of lung cancer, presents major clinical challenges owing to its highly complex tumor microenvironment and substantial cellular heterogeneity. A comprehensive understanding of the immune landscape—particularly the phenotypic diversity and functional roles of macrophage subpopulations—is critical for identifying novel therapeutic targets and developing more effective treatment strategies.

Methods

We constructed a comprehensive single-cell atlas of Stage I NSCLC using single-cell RNA sequencing (scRNA-seq) to characterize immune heterogeneity, with particular emphasis on macrophage subsets. Network pharmacology was employed to investigate the interactions between AHSA1 and bioactive compounds derived from the traditional Chinese medicine formulation Yu Ping Feng San (YPFS). To further evaluate these interactions, molecular docking simulations were performed to assess binding affinities and elucidate the potential regulatory effects on macrophage polarization.

Results

ScRNA-seq analysis revealed heterogeneous macrophage subtypes, each exhibiting distinct roles in tumor progression. AHSA1 was identified as a key regulator of macrophage polarization, with higher expression levels associated with unfavorable prognosis. Through network pharmacology and molecular docking, strong binding affinities were observed between AHSA1 and Yu Ping Feng San (YPFS)-derived compounds, including wogonin, kaempferol, and quercetin. Notably, quercetin displayed the highest binding affinity and exerted the strongest inhibitory effect on M2 macrophage polarization.

Conclusion

These findings identify AHSA1 as a pivotal regulator of macrophage polarization in NSCLC and position quercetin as a promising macrophage-targeted therapeutic candidate. Furthermore, the results highlight the potential of Yu Ping Feng San (YPFS) as a complementary therapeutic strategy for NSCLC, offering a bridge between traditional Chinese medicine and modern oncology.